| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5521073 | Drug Discovery Today | 2017 | 12 Pages |
â¢Doxorubicin (DOX) is considered one of the most effective chemotherapeutic agents.â¢Dose-cumulative cardiotoxicity is the most dangerous adverse effect.â¢DOX-based nanoformulations have been designed to diminish serious adverse effects.â¢DOX-loaded nanoproducts approved by the regulatory agencies have been described.â¢Only one nanotechnological targeted DOX product is evaluated in clinical trials.
Doxorubicin (DOX) is considered one of the most effective chemotherapeutic agents, used as a first-line drug in numerous types of cancer. Nevertheless, it exhibits serious adverse effects, such as lethal cardiotoxicity and dose-limiting myelosuppression. In this review, we focus on the description and the clinical benefits of different DOX-loaded nanotechnological platforms, not only those commercially available but also the ones that are currently in clinical phases, such as liposomes, polymeric nanoparticles, polymer-drug conjugates, polymeric micelles and ligand-based DOX-loaded nanoformulations. Although some DOX-based nanoproducts are currently being used in the clinical field, it is clear that further research is necessary to achieve improvements in cancer therapeutics.
Graphical abstractDownload high-res image (129KB)Download full-size image
